Swine Vaccines Market Size, Share and Growth Outlook 2026: By Vaccine Type, By Disease Application Type, By Animal Cohort, By Route of Administration, By Distribution Channel, Companies to 2034
The global Swine Vaccines Market size is forecast to increase from $1.99 Billion in 2026 to $3.08 Billion in 2034 at a CAGR of 5.62% between 2026 and 2034.
The Swine Vaccines market report provides detailed analysis and outlook of Swine Vaccines segments including By Vaccine Type (Inactivated (Killed) Vaccines, Live Attenuated Vaccines, Recombinant and Subunit Vaccines, Viral Vector Vaccines, DNA and mRNA Vaccines, Toxoid Vaccines), By Disease Application Type (Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus (PCV), Foot and Mouth Disease (FMD), Swine Influenza, Classical Swine Fever (CSF), Pseudorabies (Aujeszky's Disease), Bacterial Infections ), By Animal Cohort (Breeders (Sows and Boars), Piglets and Weaners, Growers and Finishers), By Route of Administration (Injectable Vaccines, Oral / Water-Delivered Vaccines, Immersion / Spray (Intranasal) Vaccines), By Distribution Channel (Veterinary Hospital and Clinic Pharmacies, Retail Pharmacies and Agro-vet Stores, Online / B2B E-Commerce Platforms) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Swine Vaccines Industry Overview
Next-Generation Vaccine Technologies Are Strengthening Swine Disease Prevention
The global swine vaccines industry is undergoing rapid transformation as producers, veterinary pharmaceutical companies, and research institutions respond to evolving viral pathogens, increasing disease complexity, and the need for stronger herd health management. Vaccination strategies are increasingly shifting from broad-spectrum disease prevention toward precision immunization platforms capable of addressing rapidly emerging viral genotypes and improving long-term production efficiency. Manufacturers are investing in multivalent formulations, accelerated vaccine development platforms, and region-specific regulatory approvals to support commercial pig production while minimizing production losses associated with endemic and emerging infectious diseases. At the same time, governments and research organizations are strengthening innovation through regulatory support and funding programs that accelerate commercialization of advanced veterinary biologics for livestock.
Innovation Is Driving Broader Protection Against Emerging Swine Pathogens
A major trend across the industry is the development of vaccines that provide broader antigenic coverage while enabling faster adaptation to changing disease epidemiology. Viral evolution, particularly among circoviruses and influenza viruses, is encouraging manufacturers to develop flexible vaccine platforms capable of maintaining protection against newly circulating strains. Reflecting this direction, Boehringer Ingelheim introduced a dual-antigen vaccine combining porcine circovirus type 2a and type 2d antigens into a single formulation, addressing the predominant viral genotypes associated with the majority of porcine circovirus-associated disease cases in commercial herds. Complementing commercial vaccine innovation, researchers at the University of Nebraska–Lincoln demonstrated a lipid nanoparticle-based synthetic DNA vaccination platform capable of generating localized immune responses within one to two weeks while allowing rapid redesign of vaccine constructs to match newly emerging hybrid swine influenza strains.
Regulatory Expansion and Localized Development Strengthen Vaccine Availability
The market is also benefiting from expanding regulatory approvals and increasing regional investment in veterinary biologics that diversify vaccine availability for livestock producers. National regulatory agencies are supporting commercialization of innovative animal health products while encouraging domestic vaccine development to improve disease preparedness. Zhengye Biotechnology strengthened this trend by securing multiple approvals for new veterinary drugs from China's Ministry of Agriculture and Rural Affairs, expanding its swine and poultry immunization portfolio with additional livestock vaccine options. Together with advances in multivalent vaccine technology and rapidly adaptable nucleic acid platforms, these developments demonstrate how the swine vaccines industry is evolving toward more responsive, scientifically advanced, and regionally diversified immunization strategies capable of addressing changing disease challenges in modern pig production.
Swine Vaccines Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Swine Vaccines market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Boehringer Ingelheim Animal Health, Zoetis Inc., Ceva Sant? Animale, Laboratorios Hipra S.A., China Animal Husbandry Industry Co. Ltd. (CAHIC), Indian Immunologicals Limited, Merck & Co. (MSD Animal Health), Elanco Animal Health, Virbac S.A., Phibro Animal Health Corporation. The Swine Vaccines market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Swine Vaccines industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in Swine Vaccines industry include- Boehringer Ingelheim Animal Health, Zoetis Inc., Ceva Sant? Animale, Laboratorios Hipra S.A., China Animal Husbandry Industry Co. Ltd. (CAHIC), Indian Immunologicals Limited, Merck & Co. (MSD Animal Health), Elanco Animal Health, Virbac S.A., Phibro Animal Health Corporation. The Swine Vaccines market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Swine Vaccines Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Swine Vaccines market remains one of the strongest-performing segments in the country.
The US Swine Vaccines Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Swine Vaccines market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Swine Vaccines industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Swine Vaccines markets
Canada's strong Swine Vaccines sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Swine Vaccines market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Swine Vaccines Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Swine Vaccines market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Swine Vaccines population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Swine Vaccines industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Swine Vaccines market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Swine Vaccines sales through 2034
France Swine Vaccines companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Swine Vaccines Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Swine Vaccines distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Swine Vaccines Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Swine Vaccines market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Swine Vaccines industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Swine Vaccines industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Swine Vaccines Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Swine Vaccines market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Swine Vaccines market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Swine Vaccines Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Swine Vaccines Market Segmentation
By Vaccine Type
Inactivated (Killed) Vaccines
Live Attenuated Vaccines
Recombinant and Subunit Vaccines
Viral Vector Vaccines
DNA and mRNA Vaccines
Toxoid Vaccines
By Disease Application Type
Porcine Reproductive and Respiratory Syndrome (PRRS)
Porcine Circovirus (PCV)
Foot and Mouth Disease (FMD)
Swine Influenza
Classical Swine Fever (CSF)
Pseudorabies (Aujeszky's Disease)
Bacterial Infections
By Animal Cohort
Breeders (Sows and Boars)
Piglets and Weaners
Growers and Finishers
By Route of Administration
Injectable Vaccines
Oral / Water-Delivered Vaccines
Immersion / Spray (Intranasal) Vaccines
By Distribution Channel
Veterinary Hospital and Clinic Pharmacies
Retail Pharmacies and Agro-vet Stores
Online / B2B E-Commerce Platforms
Leading Companies in Swine Vaccines Industry (2026)
Boehringer Ingelheim Animal Health
Zoetis Inc.
Ceva Sant? Animale
Laboratorios Hipra S.A.
China Animal Husbandry Industry Co. Ltd. (CAHIC)
Indian Immunologicals Limited
Merck & Co. (MSD Animal Health)
Elanco Animal Health
Virbac S.A.
Phibro Animal Health Corporation
Countries Included
The Swine Vaccines market report provides detailed analysis and outlook of Swine Vaccines segments including By Vaccine Type (Inactivated (Killed) Vaccines, Live Attenuated Vaccines, Recombinant and Subunit Vaccines, Viral Vector Vaccines, DNA and mRNA Vaccines, Toxoid Vaccines), By Disease Application Type (Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus (PCV), Foot and Mouth Disease (FMD), Swine Influenza, Classical Swine Fever (CSF), Pseudorabies (Aujeszky's Disease), Bacterial Infections ), By Animal Cohort (Breeders (Sows and Boars), Piglets and Weaners, Growers and Finishers), By Route of Administration (Injectable Vaccines, Oral / Water-Delivered Vaccines, Immersion / Spray (Intranasal) Vaccines), By Distribution Channel (Veterinary Hospital and Clinic Pharmacies, Retail Pharmacies and Agro-vet Stores, Online / B2B E-Commerce Platforms) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Swine Vaccines Industry Overview
Next-Generation Vaccine Technologies Are Strengthening Swine Disease Prevention
The global swine vaccines industry is undergoing rapid transformation as producers, veterinary pharmaceutical companies, and research institutions respond to evolving viral pathogens, increasing disease complexity, and the need for stronger herd health management. Vaccination strategies are increasingly shifting from broad-spectrum disease prevention toward precision immunization platforms capable of addressing rapidly emerging viral genotypes and improving long-term production efficiency. Manufacturers are investing in multivalent formulations, accelerated vaccine development platforms, and region-specific regulatory approvals to support commercial pig production while minimizing production losses associated with endemic and emerging infectious diseases. At the same time, governments and research organizations are strengthening innovation through regulatory support and funding programs that accelerate commercialization of advanced veterinary biologics for livestock.
Innovation Is Driving Broader Protection Against Emerging Swine Pathogens
A major trend across the industry is the development of vaccines that provide broader antigenic coverage while enabling faster adaptation to changing disease epidemiology. Viral evolution, particularly among circoviruses and influenza viruses, is encouraging manufacturers to develop flexible vaccine platforms capable of maintaining protection against newly circulating strains. Reflecting this direction, Boehringer Ingelheim introduced a dual-antigen vaccine combining porcine circovirus type 2a and type 2d antigens into a single formulation, addressing the predominant viral genotypes associated with the majority of porcine circovirus-associated disease cases in commercial herds. Complementing commercial vaccine innovation, researchers at the University of Nebraska–Lincoln demonstrated a lipid nanoparticle-based synthetic DNA vaccination platform capable of generating localized immune responses within one to two weeks while allowing rapid redesign of vaccine constructs to match newly emerging hybrid swine influenza strains.
Regulatory Expansion and Localized Development Strengthen Vaccine Availability
The market is also benefiting from expanding regulatory approvals and increasing regional investment in veterinary biologics that diversify vaccine availability for livestock producers. National regulatory agencies are supporting commercialization of innovative animal health products while encouraging domestic vaccine development to improve disease preparedness. Zhengye Biotechnology strengthened this trend by securing multiple approvals for new veterinary drugs from China's Ministry of Agriculture and Rural Affairs, expanding its swine and poultry immunization portfolio with additional livestock vaccine options. Together with advances in multivalent vaccine technology and rapidly adaptable nucleic acid platforms, these developments demonstrate how the swine vaccines industry is evolving toward more responsive, scientifically advanced, and regionally diversified immunization strategies capable of addressing changing disease challenges in modern pig production.
Swine Vaccines Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Swine Vaccines market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Boehringer Ingelheim Animal Health, Zoetis Inc., Ceva Sant? Animale, Laboratorios Hipra S.A., China Animal Husbandry Industry Co. Ltd. (CAHIC), Indian Immunologicals Limited, Merck & Co. (MSD Animal Health), Elanco Animal Health, Virbac S.A., Phibro Animal Health Corporation. The Swine Vaccines market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Swine Vaccines industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth Swine Vaccines Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Swine Vaccines companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional Swine Vaccines markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in Swine Vaccines industry include- Boehringer Ingelheim Animal Health, Zoetis Inc., Ceva Sant? Animale, Laboratorios Hipra S.A., China Animal Husbandry Industry Co. Ltd. (CAHIC), Indian Immunologicals Limited, Merck & Co. (MSD Animal Health), Elanco Animal Health, Virbac S.A., Phibro Animal Health Corporation. The Swine Vaccines market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Swine Vaccines Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Swine Vaccines market remains one of the strongest-performing segments in the country.
The US Swine Vaccines Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Swine Vaccines market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Swine Vaccines industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Swine Vaccines markets
Canada's strong Swine Vaccines sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Swine Vaccines market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Swine Vaccines Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Swine Vaccines market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Swine Vaccines population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Swine Vaccines industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Swine Vaccines market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Swine Vaccines sales through 2034
France Swine Vaccines companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Swine Vaccines Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Swine Vaccines distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Swine Vaccines Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Swine Vaccines market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Swine Vaccines industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Swine Vaccines industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Swine Vaccines Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Swine Vaccines market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Swine Vaccines market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Swine Vaccines Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Swine Vaccines Market Segmentation
By Vaccine Type
Inactivated (Killed) Vaccines
Live Attenuated Vaccines
Recombinant and Subunit Vaccines
Viral Vector Vaccines
DNA and mRNA Vaccines
Toxoid Vaccines
By Disease Application Type
Porcine Reproductive and Respiratory Syndrome (PRRS)
Porcine Circovirus (PCV)
Foot and Mouth Disease (FMD)
Swine Influenza
Classical Swine Fever (CSF)
Pseudorabies (Aujeszky's Disease)
Bacterial Infections
By Animal Cohort
Breeders (Sows and Boars)
Piglets and Weaners
Growers and Finishers
By Route of Administration
Injectable Vaccines
Oral / Water-Delivered Vaccines
Immersion / Spray (Intranasal) Vaccines
By Distribution Channel
Veterinary Hospital and Clinic Pharmacies
Retail Pharmacies and Agro-vet Stores
Online / B2B E-Commerce Platforms
Leading Companies in Swine Vaccines Industry (2026)
Boehringer Ingelheim Animal Health
Zoetis Inc.
Ceva Sant? Animale
Laboratorios Hipra S.A.
China Animal Husbandry Industry Co. Ltd. (CAHIC)
Indian Immunologicals Limited
Merck & Co. (MSD Animal Health)
Elanco Animal Health
Virbac S.A.
Phibro Animal Health Corporation
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Swine Vaccines Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Swine Vaccines Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL SWINE VACCINES MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Swine Vaccines Markets in 2026
3.2. Global Historic and Forecast Swine Vaccines Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Swine Vaccines Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Swine Vaccines Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Swine Vaccines Value Chain
CHAPTER 4- SWINE VACCINES MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Swine Vaccines Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- SWINE VACCINES MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Vaccine Type
Inactivated (Killed) Vaccines
Live Attenuated Vaccines
Recombinant and Subunit Vaccines
Viral Vector Vaccines
DNA and mRNA Vaccines
Toxoid Vaccines
By Disease Application Type
Porcine Reproductive and Respiratory Syndrome (PRRS)
Porcine Circovirus (PCV)
Foot and Mouth Disease (FMD)
Swine Influenza
Classical Swine Fever (CSF)
Pseudorabies (Aujeszky's Disease)
Bacterial Infections
By Animal Cohort
Breeders (Sows and Boars)
Piglets and Weaners
Growers and Finishers
By Route of Administration
Injectable Vaccines
Oral / Water-Delivered Vaccines
Immersion / Spray (Intranasal) Vaccines
By Distribution Channel
Veterinary Hospital and Clinic Pharmacies
Retail Pharmacies and Agro-vet Stores
Online / B2B E-Commerce Platforms
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA SWINE VACCINES MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Swine Vaccines Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Swine Vaccines Market Trends and Growth Opportunities to 2034
7.5. North America Swine Vaccines Market Size Outlook by Type
7.6. North America Swine Vaccines Market Size Outlook by Application
7.7. North America Swine Vaccines Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Swine Vaccines Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Swine Vaccines Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Swine Vaccines Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Swine Vaccines Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Swine Vaccines Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Swine Vaccines Companies
CHAPTER 8- EUROPE SWINE VACCINES MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Swine Vaccines Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Swine Vaccines Market Trends and Growth Opportunities to 2034
8.5. Europe Swine Vaccines Market Size Outlook by Type
8.6. Europe Swine Vaccines Market Size Outlook by Application
8.7. Europe Swine Vaccines Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Swine Vaccines Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Swine Vaccines Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Swine Vaccines Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Swine Vaccines Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Swine Vaccines Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Swine Vaccines Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Swine Vaccines Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Swine Vaccines Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Swine Vaccines Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Swine Vaccines Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Swine Vaccines Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Swine Vaccines Companies
CHAPTER 9- ASIA PACIFIC SWINE VACCINES MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Swine Vaccines Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Swine Vaccines Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Swine Vaccines Market Size Outlook by Type
9.6. Asia Pacific Swine Vaccines Market Size Outlook by Application
9.7. Asia Pacific Swine Vaccines Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Swine Vaccines Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Swine Vaccines Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Swine Vaccines Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Swine Vaccines Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Swine Vaccines Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Swine Vaccines Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Swine Vaccines Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Swine Vaccines Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Swine Vaccines Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Swine Vaccines Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Swine Vaccines Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Swine Vaccines Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA SWINE VACCINES MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Swine Vaccines Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Swine Vaccines Market Trends and Growth Opportunities to 2034
10.5. South and Central America Swine Vaccines Market Size Outlook by Type
10.6. South and Central America Swine Vaccines Market Size Outlook by Application
10.7. South and Central America Swine Vaccines Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Swine Vaccines Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Swine Vaccines Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Swine Vaccines Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Swine Vaccines Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Swine Vaccines Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Swine Vaccines Companies
CHAPTER 11- MIDDLE EAST AND AFRICA SWINE VACCINES MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Swine Vaccines Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Swine Vaccines Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Swine Vaccines Market Size Outlook by Type
11.6. Middle East and Africa Swine Vaccines Market Size Outlook by Application
11.7. Middle East and Africa Swine Vaccines Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Swine Vaccines Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Swine Vaccines Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Swine Vaccines Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Swine Vaccines Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Swine Vaccines Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Swine Vaccines Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Swine Vaccines Industry
Boehringer Ingelheim Animal Health
Zoetis Inc.
Ceva Sant? Animale
Laboratorios Hipra S.A.
China Animal Husbandry Industry Co. Ltd. (CAHIC)
Indian Immunologicals Limited
Merck & Co. (MSD Animal Health)
Elanco Animal Health
Virbac S.A.
Phibro Animal Health Corporation
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Swine Vaccines Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Swine Vaccines Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL SWINE VACCINES MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Swine Vaccines Markets in 2026
3.2. Global Historic and Forecast Swine Vaccines Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Swine Vaccines Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Swine Vaccines Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Swine Vaccines Value Chain
CHAPTER 4- SWINE VACCINES MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Swine Vaccines Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- SWINE VACCINES MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Vaccine Type
Inactivated (Killed) Vaccines
Live Attenuated Vaccines
Recombinant and Subunit Vaccines
Viral Vector Vaccines
DNA and mRNA Vaccines
Toxoid Vaccines
By Disease Application Type
Porcine Reproductive and Respiratory Syndrome (PRRS)
Porcine Circovirus (PCV)
Foot and Mouth Disease (FMD)
Swine Influenza
Classical Swine Fever (CSF)
Pseudorabies (Aujeszky's Disease)
Bacterial Infections
By Animal Cohort
Breeders (Sows and Boars)
Piglets and Weaners
Growers and Finishers
By Route of Administration
Injectable Vaccines
Oral / Water-Delivered Vaccines
Immersion / Spray (Intranasal) Vaccines
By Distribution Channel
Veterinary Hospital and Clinic Pharmacies
Retail Pharmacies and Agro-vet Stores
Online / B2B E-Commerce Platforms
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA SWINE VACCINES MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Swine Vaccines Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Swine Vaccines Market Trends and Growth Opportunities to 2034
7.5. North America Swine Vaccines Market Size Outlook by Type
7.6. North America Swine Vaccines Market Size Outlook by Application
7.7. North America Swine Vaccines Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Swine Vaccines Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Swine Vaccines Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Swine Vaccines Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Swine Vaccines Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Swine Vaccines Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Swine Vaccines Companies
CHAPTER 8- EUROPE SWINE VACCINES MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Swine Vaccines Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Swine Vaccines Market Trends and Growth Opportunities to 2034
8.5. Europe Swine Vaccines Market Size Outlook by Type
8.6. Europe Swine Vaccines Market Size Outlook by Application
8.7. Europe Swine Vaccines Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Swine Vaccines Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Swine Vaccines Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Swine Vaccines Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Swine Vaccines Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Swine Vaccines Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Swine Vaccines Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Swine Vaccines Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Swine Vaccines Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Swine Vaccines Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Swine Vaccines Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Swine Vaccines Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Swine Vaccines Companies
CHAPTER 9- ASIA PACIFIC SWINE VACCINES MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Swine Vaccines Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Swine Vaccines Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Swine Vaccines Market Size Outlook by Type
9.6. Asia Pacific Swine Vaccines Market Size Outlook by Application
9.7. Asia Pacific Swine Vaccines Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Swine Vaccines Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Swine Vaccines Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Swine Vaccines Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Swine Vaccines Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Swine Vaccines Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Swine Vaccines Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Swine Vaccines Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Swine Vaccines Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Swine Vaccines Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Swine Vaccines Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Swine Vaccines Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Swine Vaccines Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA SWINE VACCINES MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Swine Vaccines Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Swine Vaccines Market Trends and Growth Opportunities to 2034
10.5. South and Central America Swine Vaccines Market Size Outlook by Type
10.6. South and Central America Swine Vaccines Market Size Outlook by Application
10.7. South and Central America Swine Vaccines Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Swine Vaccines Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Swine Vaccines Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Swine Vaccines Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Swine Vaccines Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Swine Vaccines Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Swine Vaccines Companies
CHAPTER 11- MIDDLE EAST AND AFRICA SWINE VACCINES MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Swine Vaccines Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Swine Vaccines Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Swine Vaccines Market Size Outlook by Type
11.6. Middle East and Africa Swine Vaccines Market Size Outlook by Application
11.7. Middle East and Africa Swine Vaccines Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Swine Vaccines Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Swine Vaccines Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Swine Vaccines Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Swine Vaccines Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Swine Vaccines Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Swine Vaccines Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Swine Vaccines Industry
Boehringer Ingelheim Animal Health
Zoetis Inc.
Ceva Sant? Animale
Laboratorios Hipra S.A.
China Animal Husbandry Industry Co. Ltd. (CAHIC)
Indian Immunologicals Limited
Merck & Co. (MSD Animal Health)
Elanco Animal Health
Virbac S.A.
Phibro Animal Health Corporation
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
